The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index; 37 of the 77 sources its claims cite were checked for support.
Inflammatory biomarker response to GLP-1 receptor agonists versus other glucose-lowering medications in patients with type 2 diabetes: a systematic review and meta-analysis
Open accessAbstract
Background: Type 2 diabetes (T2D) is strongly linked to chronic inflammation and oxidative stress, which drive cardiovascular complications. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) demonstrate cardioprotective benefits that may extend beyond glycemic control, but their effects on key inflammatory and oxidative stress biomarkers compared to other glucose-lowering medications remain inconsistently reported across individual studies. Methods: A systematic review and meta-analysis of randomized controlled trials (RCTs) was conducted. Databases were searched for RCTs comparing GLP-1 RAs against other antidiabetic drugs or placebo in adults with T2D, reporting changes in inflammatory biomarkers (C-reactive protein [CRP], interleukin-6 [IL-6], tumor necrosis factor-alpha [TNF-α]) or the oxidative stress marker malondialdehyde (MDA). Data were pooled using a random-effects model, and outcomes were stratified by comparator type (placebo, insulin, other oral antidiabetic drugs [OADs]). Results: Forty RCTs (n=6029 participants) were included. GLP-1 RA therapy significantly reduced CRP levels compared to placebo (SMD = -0.59; 95% CI: -0.84 to -0.34) and other OADs (SMD = -1.06; 95% CI: -1.64 to -0.47). A significant reduction in TNF-α was observed versus placebo (SMD = -0.61; 95% CI: -0.89 to -0.32) and oral antidiabetic drugs add on (SMD = -1.62; 95% CI: -2.86 to -0.38). Data for MDA were limited and showed a non-significant trend toward reduction. GLP-1 RAs also significantly reduced IL-6 versus insulin (SMD = -0.24; 95% CI: -0.46 to -0.02). While significant heterogeneity was noted across the analyses, sensitivity analyses confirmed a consistent direction of effect, reinforcing the class-wide anti-inflammatory properties of GLP-1 RAs. Conclusion: GLP-1 RAs significantly improve key biomarkers of systemic inflammation (CRP, TNF-α) in patients with T2D compared to various active comparators and placebo. These pleiotropic effects provide a mechanistic rationale for their cardiovascular benefits and support their use as a multifaceted therapeutic strategy in T2D management. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251157476, identifier CRD420251157476.
Overview
CoChat Summary
## TL;DR
This systematic review and meta-analysis of 40 randomized controlled trials (6,029 participants) found that GLP-1 receptor agonists generally lowered inflammatory biomarkers in adults with type 2 diabetes, with the clearest and most consistent benefit seen for CRP. Effects on IL-6, TNF-α, and MDA were more mixed and often depended on comparator and outlier studies.
## Key findings
- Across 40 RCTs involving 6,029 participants, GLP-1 RAs reduced CRP versus placebo (SMD = -0.59; 95% CI: -0.84 to -0.34) and versus other oral antidiabetic drugs (SMD = -1.06; 95% CI: -1.64 to -0.47).
- TNF-α was reduced versus placebo (SMD = -0.61; 95% CI: -0.89 to -0.32) and versus oral antidiabetic drugs when used as add-on therapy (SMD = -1.62; 95% CI: -2.86 to -0.38), but other TNF-α comparisons were non-significant and highly heterogeneous.
- IL-6 was significantly reduced versus insulin (SMD = -0.24; 95% CI: -0.46 to -0.02), while other IL-6 comparisons were non-significant or sensitive to outlier removal.
- MDA showed a non-significant trend toward reduction versus insulin in the main analysis, but after sensitivity analysis excluding an outlier the pooled effect became significant (SMD = -0.73; 95% CI: -1.07 to -0.39).
## Methods
- Systematic review and meta-analysis of randomized controlled trials comparing GLP-1 receptor agonists with placebo, insulin, or other glucose-lowering drugs in adults with type 2 diabetes.
- Searches were conducted in PubMed/MEDLINE, Embase, Cochrane CENTRAL, and Web of Science from inception to August 1, 2025; 40 RCTs met inclusion criteria.
- Outcomes were pooled using random-effects models, stratified by comparator type, with risk of bias assessed using Cochrane RoB 2 and sensitivity analyses performed to exclude outliers/high-bias studies.
## Limitations
- The paper states that substantial statistical heterogeneity was the main limitation, especially for TNF-α, IL-6, and MDA, with I² often above 80–90%.
- The text notes limited generalizability because studies were geographically clustered, with 19 of 40 trials from China, and most trials had short follow-up (median 12–26 weeks).
- The study-level meta-analysis could not fully account for confounding from concurrent drugs, dietary treatments, and uncontrolled comorbidities, and publication bias could not be ruled out; these are stated in the paper.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
23 Valid · 3 Not valid · 14 Not checked · 115 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Instead of reporting distinct RCT results, the only data available are exploratory post-hoc analyses of hs-CRP that pool individual-level data across trials [Mosenzon et al., 2022 (25); Verma et al., 2023 (26)].”
§ Inflammatory biomarker response to GLP-1 receptor agonists versus other glucose-lowering medications in patients with type 2 diabetes: a systematic review and meta-analysis > Results > Study selection and characteristics
What the sources say
- Disputedcites Mosenzon et al., 2022 (25) sourceExperimental — accuracy not yet measured
The Discussion states that the exploratory hsCRP analyses used patient-level data for each individual trial and could not pool those analyses across trials because trial durations differed. Only baseline characteristics were pooled. The Results also report findings by trial, contrary to the claim that the paper does not report distinct RCT results. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
- Disputedcites Verma et al., 2023 (26) sourceExperimental — accuracy not yet measured
The Methods (Statistical analysis; page not provided) explicitly say the STEP trials were analysed separately, not pooled. The Methods (Outcomes) also say overall CRP change was a prespecified secondary endpoint in each trial, although the other analyses were post hoc. The Results report distinct CRP estimates for STEP 1, 2, and 3. (LLM, conf=0.91)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“insulin therapy, though essential, has rarely demonstrated superior efficacy in lowering inflammatory markers like TNF-α and CRP compared to other treatments and is associated with weight gain (14, 15).”
§ Inflammatory biomarker response to GLP-1 receptor agonists versus other glucose-lowering medications in patients with type 2 diabetes: a systematic review and meta-analysis > Introduction
What the sources say
- Not checked — no full text of the sourcecites [14] Gurkan, 2014, Evaluation of exenatide versus insulin glargine for the impact on endothelial functions and cardiovascular risk markers, Diabetes Res Clin Pract source
- Disputedcites [15] Kang, 2021, Effects of exenatide on urinary albumin in overweight/obese patients with T2DM: a randomized clinical trial, Sci Rep sourceExperimental — accuracy not yet measured
Table 2 in Results > Other efficacy variables (page unavailable) reports a mean weight change of −0.658 kg at week 24 in the insulin glargine group, not weight gain; the change was not statistically significant (P = 0.221). This trial therefore does not show the weight gain attributed to insulin therapy, although its result does not settle whether insulin therapy is associated with weight gain more generally. (LLM, conf=0.84)
Checked by a reasoning model — may be wrong.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“it appears less effective than agents like exenatide in reducing hs-CRP (13).”
§ Inflammatory biomarker response to GLP-1 receptor agonists versus other glucose-lowering medications in patients with type 2 diabetes: a systematic review and meta-analysis > Introduction
What the sources say
- Supportedcites [13] Fan, 2013, Exenatide improves type 2 diabetes concomitant with non-alcoholic fatty liver disease, Arquivos Brasileiros Endocrinologia Metabologia source
In “Variables after the 12-week treatment,” hs-CRP was lower in the exenatide group than in the metformin group (2.18 ± 0.34 vs. 2.69 ± 0.53; P = 0.01). The study compared patients with type 2 diabetes and concomitant NAFLD, so the finding supports the hedged comparison in that population. (LLM, conf=0.93)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“another found no significant change versus a DPP-4 inhibitor (20).”
§ Inflammatory biomarker response to GLP-1 receptor agonists versus other glucose-lowering medications in patients with type 2 diabetes: a systematic review and meta-analysis > Introduction
What the sources say
- Supportedcites [20] Takeshita, 2015, Vildagliptin vs liraglutide as a second-line therapy switched from sitagliptin-based regimens in patients with type 2 diabetes: A randomized, parallel-group study, J Diabetes Investig source
Table 1 (Results > Clinical Outcomes; page not provided) reports no statistically significant change in TNF-α within the liraglutide group (P = 0.602) and no significant difference between liraglutide and the DPP-4 inhibitor vildagliptin (P = 0.319). (LLM, conf=0.93)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“insulin therapy, though essential, has rarely demonstrated superior efficacy in lowering inflammatory markers like TNF-α and CRP compared to other treatments and is associated with weight gain (14, 15).”
§ Inflammatory biomarker response to GLP-1 receptor agonists versus other glucose-lowering medications in patients with type 2 diabetes: a systematic review and meta-analysis > Introduction
What the sources say
- Not checked — no full text of the sourcecites [14] Gurkan, 2014, Evaluation of exenatide versus insulin glargine for the impact on endothelial functions and cardiovascular risk markers, Diabetes Res Clin Pract source
- Partly supportedcites [15] Kang, 2021, Effects of exenatide on urinary albumin in overweight/obese patients with T2DM: a randomized clinical trial, Sci Rep sourceExperimental — accuracy not yet measured
The Study design section identifies insulin glargine as the comparator, and Results > Other efficacy variables reports significantly greater changes in CRP and TNF-α with exenatide in this 24-week trial. One comparison does not establish that insulin therapy has *rarely* shown superior efficacy across other treatments; no page number is available in our copy. (LLM, conf=0.86)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
76 more claims · 9 with their cited sources checked
Create a free account to see all 155 claims and to verify the 4 references still open.
- It may state two separate claims as one. 64
- Probably not a substantial claim. 26
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Our results are broadly consistent with earlier meta‐analyses that reported reductions in CRP/hs‐CRP and some cytokines with GLP‐1RAs in T2DM [14, 63, 64].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Inflammatory biomarker response to GLP-1 receptor agonists versus other glucose-lowering medications in patients with type 2 diabetes: a systematic review and meta-analysis > Abstract > Results
“GLP-1 RA therapy significantly reduced CRP levels compared to placebo (SMD = -0.59; 95% CI: -0.84 to -0.34)”
§ Inflammatory biomarker response to GLP-1 receptor agonists versus other glucose-lowering medications in patients with type 2 diabetes: a systematic review and meta-analysis > Results > C-reactive protein
“The analysis of 5 studies comparing GLP-1 RAs to placebo (Figure 1A) yielded a significant reduction in CRP (SMD = -0.59; 95% CI, -0.84 to -0.43), with low non-significant heterogeneity (I² = 27.6%).”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Inflammatory biomarker response to GLP-1 receptor agonists versus other glucose-lowering medications in patients with type 2 diabetes: a systematic review and meta-analysis > Methodology > Search strategy
“From the inception to August 1, 2025, we searched four electronic databases for relevant literature: PubMed/MEDLINE, Embase, Cochrane CENTRAL, Web of Science.”
§ Inflammatory biomarker response to GLP-1 receptor agonists versus other glucose-lowering medications in patients with type 2 diabetes: a systematic review and meta-analysis > Results > Study selection and characteristics
“The initial systematic literature search across PubMed, Embase, and the Cochrane Library yielded 1,148 records.”
Citations
Cites
le Roux, C. W., Astrup, A., Fujioka, K., Greenway, F., Lau, D. C. W., Van Gaal, L., Ortiz, R. V., Wilding, J. P. H., Skjøth, T. V., Manning, L. S., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30069-7 · Cited by 850
Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action
Ussher, J. R., & Drucker, D. J. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00849-3 · Cited by 577
Yao, H., Zhang, A., Li, D., Wu, Y., Wang, C.-Z., Wan, J.-Y., & Yuan, C.-S. (2024) · BMJ · doi:10.1136/bmj-2023-076410 · Cited by 558
The anti-inflammatory and immunological properties of GLP-1 Receptor Agonists
Bendotti, G., Montefusco, L., Lunati, M. E., Usuelli, V., Pastore, I., Lazzaroni, E., Assi, E., Seelam, A. J., El Essawy, B., Jang, J., et al. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106320 · Cited by 406
Neuen, B. L., Heerspink, H. J. L., Vart, P., Claggett, B. L., Fletcher, R. A., Arnott, C., de Oliveira Costa, J., Falster, M. O., Pearson, S.-A., Mahaffey, K. W., et al. (2024) · Circulation · doi:10.1161/circulationaha.123.067584 · Cited by 358
Heilbronn, L. K., Noakes, M., & Clifton, P. M. (2001) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.21.6.968 · Cited by 331 · cited 1×
“Strong associations between subsequent reductions in body weight, HbA1c, and visceral fat and reductions in in fl ammatory biomarkers were found in several of the trials included in our evaluation (7, 28, 35, 51, 52).”
Using Risk of Bias 2 to assess results from randomised controlled trials: guidance from Cochrane
Flemyng, E., Moore, T. H., Boutron, I., Higgins, J. P., Hróbjartsson, A., Nejstgaard, C. H., & Dwan, K. (2023) · BMJ Evidence-Based Medicine · doi:10.1136/bmjebm-2022-112102 · Cited by 264
Dutour, A., Abdesselam, I., Ancel, P., Kober, F., Mrad, G., Darmon, P., Ronsin, O., Pradel, V., Lesavre, N., Martin, J. C., et al. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12680 · Cited by 262
Yan, J., Yao, B., Kuang, H., Yang, X., Huang, Q., Hong, T., Li, Y., Dou, J., Yang, W., Qin, G., et al. (2019) · Hepatology · doi:10.1002/hep.30320 · Cited by 260
Effects of Glucagon-Like Peptide-1 on Oxidative Stress and Nrf2 Signaling
Oh, Y., & Jun, H.-S. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms19010026 · Cited by 217 · cited 1×
“The Nrf2 signaling pathway, a master regulator of cellular antioxidant defense mechanisms, is upregulated by GLP-1 receptor activation, according to preclinical research (49).”
Research works printed but not linked: 2
- Wang, 2020, Comparison between the effects of sitagliptin and liraglutide on blood glucose and cognitive function of patients with both type 2 diabetes mellitus and post-stroke mild cognitive impairment, Int J Clin Exp Med, 13
- Suzuki, 2014, Greater efficacy and improved endothelial dysfunction in untreated type 2 diabetes with liraglutide versus sitagliptin, Dokkyo J Med Sci, 41
Cited by
Kanbay, M., Shah, E., AlShiab, R., Ozbek, L., Ay, S., Rustamov, A., Covic, A., Mallamaci, F., & Zoccali, C. (2026) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.71106 · Cited by 4
Retuerto, M., Fernández, I. G., Ramos, M. A., Fernández, I. G., Blanco, A. V., Sanz, A. M., Rivero-Lezcano, O. M., & Díez‐Álvarez, E. (2026) · RMD Open · doi:10.1136/rmdopen-2026-007122
Metadata
- Authors
- Alrasheed, T., Mostafa, M. E. A., Madkhali, M. A., & Khairy, H. A.
- Affiliations
- University of Tabuk (SA)
- Jazan University (SA)
- Imam Mohammad ibn Saud Islamic University (SA)
- Corresponding author
- Khairy, Hesham A
- Venue
- Frontiers in Endocrinology
- Publisher
- Frontiers Media SA
- Published
- 2026-01-15
- Volume
- 16
- Pages
- 1734549-1734549
- ISSN
- 1664-2392 (ISSN-L)
- PMC
- PMC12852008
- OpenAlex
- W7124242929
- Semantic Scholar
- e3a429bfe5e056fd74018a5ec2374fec0386e22b
- Cited by
- 4
- References
- 54
- Citations by year
- 2026: 4
- FWCI
- 4.24
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Endocrinology (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- GLP-1 receptor agonists, type 2 diabetes, inflammation, oxidative stress, C-reactive protein, TNF-α, interleukin-6, malondialdehyde, glucose-lowering medications, oral antidiabetic drugs, insulin, cardioprotection, pleiotropy, cardiovascular risk reduction, glycemic control, hypolipidemic effect, antithrombotic activity
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, C-Reactive Protein, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Inflammation, Tumor Necrosis Factor-alpha, Biomarkers, Randomized Controlled Trials as Topic, Oxidative Stress
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Inflammatory biomarker response to GLP-1 receptor agonists versus other glucose-lowering medications in patients with type 2 diabetes: a systematic review and meta-analysis. https://app.cochat.ai/papers/10.3389/fendo.2025.1734549
- The paper
- Alrasheed, T., Mostafa, M. E. A., Madkhali, M. A., & Khairy, H. A. (2026). Inflammatory biomarker response to GLP-1 receptor agonists versus other glucose-lowering medications in patients with type 2 diabetes: a systematic review and meta-analysis. Frontiers in Endocrinology. https://doi.org/10.3389/fendo.2025.1734549
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.